MannKind Corporation [MNKD]

The screen's +44.8pp valuation margin does not survive the filings. 76.8% of MannKind's FY2022-FY2025 revenue increase came from one counterparty (United Therapeutics, via a 10% Tyvaso DPI royalty and a cost-plus manufacturing contract) and a further 9.3% came from the scPharmaceuticals acquisition closed 7 October 2025; organic own-product revenue contributed 13.9%. Strip the acquisition and Q1 2026 revenue FELL 4.7% year-on-year. The screen also records +$57.4m of net cash against a filed position of $325.0m of principal borrowings versus $133.9m of cash and investments — a $246.5m error. Correcting both moves the required 5-year CAGR from 7.0% to 11.8% and the demonstrated rate from 51.8% to organic TTM +8.2%, turning the margin from +44.8pp to −3.6pp.

Key findings

• 76.8% of the FY2022–FY2025 revenue increase is United Therapeutics (45.2% royalty + 31.6% cost-plus manufacturing); a further 9.3% is the scPharmaceuticals acquisition; organic own-product revenue contributed 13.9%.
• Strip the acquisition and Q1 2026 revenue FELL 4.7% year-on-year ($74.7m vs $78.4m). Organic TTM growth is +8.2%, not 51.8%.
• The screen's net cash of +$57.4m is wrong by $246.5m. The 10-Q states $133.9m of cash and investments against $325.0m of principal borrowings — $189.1m of NET DEBT. MannKind has had negative book equity for 21 consecutive quarters.
• Correcting the balance sheet and share count moves the required 5-year CAGR from 7.0% to 11.8%. The +44.8pp margin becomes −3.6pp.
• The screen's operating margin of 11.1% is the FY2025 figure applied to TTM revenue. TTM operating margin is 4.1%, so EV/EBIT is 97.0x, not 28.7x.
• The bear case is in MannKind's own 10-K: United Therapeutics called Tresmi — a soft-mist treprostinil MannKind earns nothing on — a 'category killer' versus dry-powder inhalers, with a 2026 filing and 2027 launch planned.
• Tyvaso DPI mentions in MannKind's own earnings releases collapsed from 11-12 to 3-4 and have stayed there for six consecutive quarters, while the line grew to 64% of revenue. 'Tresmi' appears zero times in any earnings release.
• Five days before the screen ran, MannKind issued 12.85m shares (4.2%) at a 0.6% DISCOUNT to market to raise $50m — to fund a $45m CVR bill triggered by its own Furoscix ReadyFlow approval. Net new capital to the business: about $2m.
• $25.3m of TTM revenue (7.0%) is non-cash or pass-through: $13.1m remitted to Sagard and ~$12.2m of deferred-revenue amortisation.
• The revenue is NOT milestone-driven — identifiable milestone revenue is $1.0m of $349.0m in FY2025. The problem is not lumpiness; it is that the recurring revenue is somebody else's.
• Furoscix is real: ~+70% year-on-year underlying, with ReadyFlow FDA-approved 23 July 2026 de-risking $129.6m of capitalised IPR&D. But it is 11% of revenue and would have to grow roughly 5x by FY2031 to justify the price with the UT block merely flat.
• Watch item: Furoscix ran at $273k/day in the Q4 2025 stub and $172k/day in Q1 2026 — a 37% per-day sequential decline in the first full quarter of ownership.

Sections

Disclosed limitations

• No analyst consensus — Alpha Vantage quota exhausted 2026-07-29. The NTM revenue base of $410m is a HOUSE build from disclosed run rates, not consensus, and is labelled as such throughout.
• The expiry date of the underlying 10% United Therapeutics royalty is NOT DISCLOSED in either the FY2025 10-K or the Q1 2026 10-Q. Only the Sagard 1% term (to 31 Dec 2042) is disclosed. Noted as a gap, not assumed.
• No Q2 2026 financials. The last filed balance sheet is 31 March 2026. All pro-forma figures layer only the July placement and the $45m CVR payment onto it and therefore EXCLUDE Q2 2026 operating burn, which is unknown.
• The Q2 2026 earnings date is PATTERN-INFERRED from filings on 2025-08-06, 2024-08-07 and 2023-08-07. It is not company-confirmed and no date is asserted.
• The ~$16m CVR fair-value remeasurement charge is DERIVED (contingent consideration carried at $29.0m against a now-triggered $45.0m obligation), not company-disclosed.
• Afrezza / V-Go / Furoscix TTM splits are reconstructed from MD&A gross revenue, gross-to-net percentages and stated dollar changes, then cross-checked to sum to the tagged Commercial product sales total. They carry about ±$1m of rounding.
• The 22.6x EBIT exit multiple is the SCREEN'S and its GROWTH_MATCHED basis over 130 peers is NOT verified here. This memo declares the EBIT-basis exit multiple UNIDENTIFIED and anchors on MannKind's own EV/Sales history instead.
• Momentum percentile is INDETERMINATE — no cross-sectional universe distribution was computed, and criteria.md requires momentum be assessed cross-sectionally.
• Peer Spread Criteria is INDETERMINATE — no comparable name in the same end-market was underwritten in this run.
• No external professional 12-month target exists for the sanity band. That check is not performed and is declared missing rather than substituted with a peer-derived figure.
• No Excel workbook and no forward DCF were built. Per criteria.md the reverse DCF is mandatory as the primary output where terminal value dominates, which it does entirely here (TTM EBIT $14.8m against a $1,440m EV). Every derived number is fully specified in MNKD_Financial_Model_Notes.md.
• Alpaca IEX vs SIP: all price, volume and volatility figures use SIP. The IEX feed returns about 5% of true volume for this name (202k vs 4.08m shares/day median) and would understate liquidity roughly 20-fold.